BRAF and thyroid gland carcinoma: Indeed, the results of a pilot clinical trial using a MAPK inhibition redifferentiation strategy in patients with BRAF p.V600E radioiodine-refractory thyroid carcinoma suggests that SWI/SNF gene mutation may be a marker of resistance to these forms of treatment (178).